Real-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United States.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a persistent and heterogeneous condition diagnosed by exclusion, defined by a bladder-associated unpleasant sensation (e.g. pain, pressure, or discomfort), and affecting patients' quality of life. This real-world study aimed to describe all-cau…
Bladder to Breast Milk-DMSO Treatment of Interstitial Cystitis.
This study aimed to be the first to quantify dimethyl sulfoxide (DMSO) concentrations in human milk after the maternal dosing and estimate the relative infant dose (RID) to assess potential safety concerns. Human milk samples were obtained at different time points after the mother had received one R…
Preclinical models of female pelvic pain disorders.
Pain is influenced by a complex interplay of biological, psychological, and social factors. Sex has emerged as a key determinant of vulnerability to chronic pain and a major risk factor for poor response to available pharmacological treatments. Women report higher rates of chronic pain and exhibit g…
Effect of Intravesical Administration of Steroid Enemas on an Experimental Autoimmune Interstitial Cystitis-Like Mouse Model.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, non-bacterial cystitis presenting with bladder pain, frequent urination, and Hunner's lesions. Current therapies, including dimethyl sulfoxide (DMSO) instillation, provide temporary relief but often cause procedural pain. Steroid ene…
Corrigendum to "Diagnosis of interstitial cystitis/bladder pain syndrome: Guidelines from the Committee of Female Urology (CUROPF) of the French Association of Urology (AFU)" [The French Journal of Urology 36 (2026) 103166].
Corrigendum to "Treatment of interstitial cystitis/bladder pain syndrome: Guidelines from the Committee of Female Urology (CUROPF) of the French Association of Urology (AFU)" [The French Journal of Urology 36 (2026) 103169].
Mesenchymal stem Cells and Extracellular Vesicles in Bladder Dysfunction: Mechanisms and Translational Perspectives.
Bladder dysfunction comprises diverse lower urinary tract disorders lacking treatments that restore tissue integrity and neural control. While mesenchymal stem cells (MSCs) show promise in regenerative urology, their benefits primarily stem from paracrine mechanisms. Consequently, MSC-derived extrac…